Docetaxel Injection is indicated for:

• Breast Cancer: single agent for locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node positive breast cancer.
• Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC.
• Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer. 
• Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction. 
• Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN.

Breast Cancer:

• The recommended dose of Docetaxel Injection for locally advanced or metastatic breast cancer after failure of prior chemotherapy is 60 mg/m² to 100 mg/m² administered intravenously over 1 hour every 3 weeks.
• The recommended Docetaxel Injection dose for the adjuvant treatment of operable node-positive breast cancer is 75 mg/m² given 1 hour after doxorubicin 50 mg/m² and cyclophosphamide 500 mg/m2 every 3 weeks for 6 courses. G-CSF prophylaxis may be used to reduce the risk of hematological toxicities.

Non-Small Cell Lung Cancer 

• Docetaxel was evaluated as monotherapy for treatment after failure of prior platinum-based chemotherapy, and the recommended dose is 75 mg/m² administered intravenously over 1 hour every 3 weeks. In randomized, controlled trials, a dose of 100 mg/m² was associated with increased hematologic toxicity, infection, and treatment-related mortality in patients who had previously received chemotherapy.
• Docetaxel was tested in combination with cisplatin in chemotherapy-naive patients. The recommended dose of Docetaxel Injection is 75 mg/m2 intravenously over 1 hour, followed by cisplatin 75 mg/m² intravenously over 30-60 minutes every 3 weeks.

Prostate cancer 

• For hormone-refractory metastatic prostate cancer, the recommended dose of Docetaxel Injection is 75 mg/m2 every 3 weeks as a 1 hour intravenous infusion. Prednisone 5 mg orally twice daily is administered continuously.

Gastric adenocarcinoma 

• Docetaxel Injection 75 mg/m2 as a 1 hour intravenous infusion is recommended for gastric adenocarcinoma, followed by cisplatin 75 mg/m2 as a 1 to 3 hour intravenous infusion (both on day 1), followed by fluorouracil 750 mg/m2 per day given as a 24-hour continuous intravenous infusion for 5 days, beginning at the end of the cisplatin infusion. Every three weeks, the treatment is repeated. For cisplatin administration, patients must be premedicated with antiemetics and adequately hydrated.

Head and Neck Cancer 

Injection is 75 mg/m² as a 1 hour intravenous infusion on day 1, followed by cisplatin 100 mg/m² administered as a 30-minute to 3 hour infusion, followed by fluorouracil 1000 mg/m²/day as a continuous infusion from day 1 to day 4. This regimen is administered every 3 weeks for 3 cycles. Following chemotherapy, patients should receive chemoradiotherapy.